← FDA DRUG APPROVALS

FDA ANDA · ANDA072579

NIFEDIPINE

Sponsor: ACTAVIS ELIZABETH

APPLICATION
ANDA072579
TYPE
ANDA
ORIGINAL APPROVAL
1989-04-28
LATEST ACTION
2016-04-12
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

NIFEDIPINEPrescription
NIFEDIPINE 10MG · CAPSULE · ORAL

Approval history

2016-04-12Labeling · Supplement 36 · standardAP
2014-12-11Labeling · Supplement 35 · standardAP
2011-12-13Labeling · Supplement 33AP
2004-08-04Labeling · Supplement 25AP
2003-01-06Manufacturing (CMC) · Supplement 20AP
2002-08-20Labeling · Supplement 19AP
2001-11-02Manufacturing (CMC) · Supplement 16AP
2001-08-22Labeling · Supplement 17AP
2000-01-24Manufacturing (CMC) · Supplement 15AP
1998-02-09Labeling · Supplement 14AP
1997-10-01Labeling · Supplement 13AP
1996-10-18Labeling · Supplement 12AP
1996-08-28Labeling · Supplement 11AP
1996-04-22Labeling · Supplement 10AP
1996-01-18Manufacturing (CMC) · Supplement 9AP
1992-08-10Labeling · Supplement 7AP
1992-07-14Labeling · Supplement 6AP
1992-05-12Labeling · Supplement 2AP
1992-03-24Labeling · Supplement 5AP
1992-03-18Manufacturing (CMC) · Supplement 3AP
1992-02-11Labeling · Supplement 4AP
1989-04-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →